Today Leerink Swann Reconfirms a “Outperform” Rating on Neurocrine Biosciences (NASDAQ:NBIX) and a $83 Target Price

November 15, 2017 - By Vivian Currie

 Today Leerink Swann Reconfirms a

Investors sentiment increased to 1.25 in 2017 Q2. Its up 0.22, from 1.03 in 2017Q1. It improved, as 33 investors sold Neurocrine Biosciences, Inc. shares while 59 reduced holdings. 44 funds opened positions while 71 raised stakes. 91.92 million shares or 11.33% more from 82.57 million shares in 2017Q1 were reported.

Price T Rowe Assoc Md owns 7.17M shares. Dafna Cap Management Lc invested 1.79% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Soros Fund Mgmt Ltd Co owns 4,900 shares. Northwestern Mutual Wealth Management has 0% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 96 shares. Federated Investors Pa accumulated 0.02% or 123,557 shares. Timessquare Mngmt reported 0.69% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Franklin Res, California-based fund reported 3.38M shares. Advisory Research invested in 21,768 shares. Capital Ww owns 0.01% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 688,000 shares. Moreover, Canada Pension Plan Invest Board has 0% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Ellington Mgmt Ltd Co holds 0.11% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 17,100 shares. Teacher Retirement System Of Texas invested in 6,966 shares or 0% of the stock. Moreover, Nordea Investment Management has 0% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Glenmede Trust Com Na reported 600 shares. Jane Street Grp Incorporated Ltd Liability Corporation has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Since May 18, 2017, it had 0 insider buys, and 1 sale for $533,900 activity. $533,900 worth of stock was sold by Grigoriadis Dimitri E. on Tuesday, May 23. OBrien Christopher Flint also sold $5.63 million worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares. 10,000 shares were sold by Lippoldt Darin, worth $532,700.

Neurocrine Biosciences (NASDAQ:NBIX) Rating Reaffirmed

In a report revealed on 2 November, The “Outperform” rating of Neurocrine Biosciences (NASDAQ:NBIX) shares was restate at Leerink Swann, who now has a $83 target on the stock. Leerink Swann’s target would indicate a possible upside of 13.51 % from the current price of the company.

Investors sentiment increased to 1.25 in 2017 Q2. Its up 0.22, from 1.03 in 2017Q1. It improved, as 33 investors sold Neurocrine Biosciences, Inc. shares while 59 reduced holdings. 44 funds opened positions while 71 raised stakes. 91.92 million shares or 11.33% more from 82.57 million shares in 2017Q1 were reported.

Price T Rowe Assoc Md owns 7.17M shares. Dafna Cap Management Lc invested 1.79% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Soros Fund Mgmt Ltd Co owns 4,900 shares. Northwestern Mutual Wealth Management has 0% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 96 shares. Federated Investors Pa accumulated 0.02% or 123,557 shares. Timessquare Mngmt reported 0.69% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Franklin Res, California-based fund reported 3.38M shares. Advisory Research invested in 21,768 shares. Capital Ww owns 0.01% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 688,000 shares. Moreover, Canada Pension Plan Invest Board has 0% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Ellington Mgmt Ltd Co holds 0.11% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 17,100 shares. Teacher Retirement System Of Texas invested in 6,966 shares or 0% of the stock. Moreover, Nordea Investment Management has 0% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Glenmede Trust Com Na reported 600 shares. Jane Street Grp Incorporated Ltd Liability Corporation has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Since May 18, 2017, it had 0 insider buys, and 1 sale for $533,900 activity. $533,900 worth of stock was sold by Grigoriadis Dimitri E. on Tuesday, May 23. OBrien Christopher Flint also sold $5.63 million worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares. 10,000 shares were sold by Lippoldt Darin, worth $532,700.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 12 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 12 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci has $139.0 highest and $58.0 lowest target. $82’s average target is 12.14% above currents $73.12 stock price. Neurocrine Biosci had 38 analyst reports since August 18, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, June 26 by Jefferies. The firm earned “Buy” rating on Tuesday, August 18 by Jefferies. The rating was maintained by BMO Capital Markets on Tuesday, October 3 with “Buy”. Piper Jaffray maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Thursday, October 8 with “Overweight” rating. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Overweight” rating given on Thursday, November 2 by Barclays Capital. The company was initiated on Tuesday, November 22 by Oppenheimer. The firm earned “Buy” rating on Wednesday, July 5 by Oppenheimer. The stock has “Outperform” rating by BMO Capital Markets on Thursday, April 7. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by Oppenheimer on Thursday, November 2. The firm has “Buy” rating by Robert W. Baird given on Monday, October 23.

About 28,053 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 12.51% since November 15, 2016 and is uptrending. It has underperformed by 4.19% the S&P500.

Analysts expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report $-0.03 EPS on February, 13.They anticipate $0.48 EPS change or 94.12 % from last quarter’s $-0.51 EPS. After having $-0.13 EPS previously, Neurocrine Biosciences, Inc.’s analysts see -76.92 % EPS growth.

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development platform, focused on neurological and endocrine based diseases and disorders. The company has market cap of $6.47 billion. The Company’s three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease. It currently has negative earnings. The Company’s product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia.

More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: Prnewswire.com which released: “Neurocrine Biosciences Announces Conference Call and Webcast to Report Third …” on October 24, 2017, also Prnewswire.com with their article: “Neurocrine Biosciences to Present at the Jefferies 2017 London Healthcare …” published on November 08, 2017, Prnewswire.com published: “Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment …” on November 14, 2017. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: Streetinsider.com and their article: “Neurocrine Biosciences (NBIX) Announces FDA Orphan Drug Designation for …” published on October 23, 2017 as well as Seekingalpha.com‘s news article titled: “Neurocrine’s Ingrezza Launch Continues To Exceed Expectations” with publication date: November 02, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.